Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Articles|April 26, 2021
Pharmacy Times: Week of April 26 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Chris Antypas about the critical role community pharmacists play in bridging the education gap and ensuring access to the COVID-19 vaccine.
- A new episode of the Pharmacy Focus podcast with Nick Sinagra, spinal muscular atrophy patient, about his treatment journey and experiences with 2 different SMA treatments.
- An article that discusses how specialty pharmacy is uniquely positioned to capture and deliver data to drive value in the care of patients in need of specialty medications. Data can provide visibility into the process, day-to-day operations, and the patient journey, as well as aid specialty pharmacies in meeting contractual obligations to provide a closer look at performance and improvement opportunities.
Advertisement
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
A current pharmacy resident provides insights on how pharmacy students can manage the transition from student to resident.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
4
Beyond Prescription Volume: Measuring the Pharmacist’s Value
5